Wednesday, December 13, 2023

Windjammer Capital Acquires Bio X Cell

Newport Beach-based private equity investor Windjammer Capital said this morning that it has acquired Bio X Cell, a producer of monoclonal antibodies (mAbs). Financial details of the deal were not announced. Windjammer said it acquired the company in partnership with management. The deal closed on November 6, according to Windjammer. Windjamer says it invests control equity in middle-market businesses and in partnership with management, and has over $3 billion in committed capital.